540788 logo

Aspira Pathlab & Diagnostics Limited Stock Price

BSE:540788 Community·₹708.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

540788 Share Price Performance

₹65.41
21.68 (49.58%)
₹65.41
21.68 (49.58%)
Price ₹65.41

540788 Community Narratives

There are no narratives available yet.

Recent 540788 News & Updates

Aspira Pathlab & Diagnostics Limited Key Details

₹226.1m

Revenue

₹122.8m

Cost of Revenue

₹103.3m

Gross Profit

₹79.4m

Other Expenses

₹24.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.33
Gross Margin
45.70%
Net Profit Margin
10.60%
Debt/Equity Ratio
26.3%

Aspira Pathlab & Diagnostics Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with acceptable track record.

3 Risks
2 Rewards

About 540788

Founded
1973
Employees
141
CEO
Pankaj Shah
WebsiteView website
www.aspiradiagnostics.com

Aspira Pathlab & Diagnostics Limited owns, manages, runs, and administers various diagnostics centers primarily in India. The company offers biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigation services. It also provides sonography, x-ray, and radiology tests. The company was formerly known as Utkal Soap Products Limited and changed its name to Aspira Pathlab & Diagnostics Limited in November 2016. Aspira Pathlab & Diagnostics Limited was incorporated in 1973 and is based in Mumbai, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.8%
  • 3 Months: -1.3%
  • 1 Year: -2.3%
  • Year to Date: 1.1%
The market is up 1.8% over the last week, with the Financials sector leading the way, up 2.6%. The market has been flat overall in the last year. Earnings are forecast to grow by 16% annually. Market details ›